INCY News and Press, Incyte Corporation From 07/09/21

Innovent Biologics (IVBIY) announces that the National Medical Products Administration ((NMPA)) of China has accepted the New Drug Application ((NDA)) for FGFR1/2/3 inhibitor (pemigatinib) for the treatment of certain adults with cholangiocarcinoma.Pemigatinib looks to treat pa...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion in assets under management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe now holdi...

bloodua/iStock via Getty Images The European Commission has selected five medications that its considers preferred therapies in the treatment of COVID-19, Reuters reports. The medicines include Eli Lilly (LLY) and Incyte's (INCY) Oluminant (baricitinib), Regeneron's (REGN) REGN-COV2 (casirivi...

Dr_Microbe/iStock via Getty Images On Tuesday, the European Commission listed four monoclonal antibody treatments and a repurposed drug against COVID-19 as it plans to create an initial portfolio of preferred drugs for the disease, Reuters reports. With the selection, the regional body a...

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for&...

- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combi...

Incyte ([[INCY]] +1.0%) said that the U.S. FDA's advisory committee had voted in favor of putting off the regulatory decision on the company's squamous cell carcinoma of the anal canal ((SCAC)) treatment retifanlimab, citing the need for more data.The Oncologic Drugs Advisory C...

Incyte (Nasdaq:INCY) today announced the outcome of a meeting of the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA), which reviewed the Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Big Tech will be in the spotlight next with the U.S. House Judiciary Committee expected to vote on a package on antitrus...